Home > Newsroom > Publications

U-M CCC - Michigan Oncology Journal Fall 2000

OF INTEREST

Clinical Trials

Phase I trial for patients with relapsed neuroblastoma or neuroblastoma that has failed induction therapy.
Patients will receive a tumor-specific radio-labeled analogue (I-131 MIBG) in combination with high-dose chemotherapy and a bone marrow transplant. The MIBG is administered as an intravenous infusion 21 days prior to transplant. To be eligible, patients must be 1 to 18 years of age, have either a relapsed neuroblastoma or have failed induction therapy. Patients are eligible if they have had a prior transplant and if they are > 6 months post transplant. All patients must have MIBG avid tumors. Tumor response will be investigated by MIBG scans post transplant.
Contact Cancer AnswerLine 800-865-1125.

Tumor vaccine trial for patients with intermediate-grade non-Hodgkin's lymphoma, who are in first relapse and eligible for autologous bone marrow transplant.
These patients must have at least a 2 cm lymphomatous lymph node that can be excised, prior to any induction therapy, to prepare a tumor vaccine. Patients then undergo induction chemotherapy (must achieve at least a partial response) followed by autologous transplant. Three vaccinations, prepared from dendritic cells pulsed with irradiated autologous tumor, are given two weeks apart beginning ~day 100 after transplant in the hope of treating minimal residual disease.
Contact Cancer AnswerLine 800-865-1125.

Phase II immunotherapy trial for patients with metastatic breast cancer and tumor accessible to injection.
Appropriate metastasis sites are subcutaneous nodules >1 cm or accessible lymph nodes. Dendritic cells will be harvested from the patient by leukapheresis, then presented with KLH in vitro prior to injection directly into suitable metastatic nodules. Endpoints include clinical response and serological evaluation for immune response to KLH and tumor antigens. The injected lesion will be surgically removed at the end of treatment to evaluate for apoptosis.
Contact Cancer AnswerLine 800-865-1125.

New Faculty

Andrzej J. Jakubowiak, M.D., Ph.D.
Clinical Assistant Professor, Internal Medicine, Division of Hematology and Oncology

Previously completed a fellowship in Hematology and Oncology at the Memorial Sloan-Kettering Cancer Center, New York

Expertise: hematological malignancies

Professional Interests: new treatment strategies for multiple myeloma

Darius Karimipour, M.D.
Lecturer, Dermatology

Previously completed a residency in dermatology at the University of Michigan and two years of specialty training in the University of Michigan Multidisciplinary Melanoma Clinic

Expertise/Professional Interests: melanoma, non-melanoma skin cancer, Mohs surgery and reconstructive surgery

Jeffrey S. Orringer, M.D.
Lecturer, Dermatology

Previously completed medical school at Harvard and a dermatology residency at the University of Michigan

Expertise/Professional Interests: cutaneous oncology, dermatologic surgery, cosmetic dermatology, and laser surgery

return to top

Continue reading:

Antibody Therapy for Non-Hodgkin's Lymphoma

Treatment of Intermediate- and High-grade Non-Hodgkin's Lymphoma

New Small Lymphocytic Lymphomas

The Revised European-American Classification of Lymphoid Neoplasms (REAL Classification)